InSilico Medicine Wins China IND Nod for AI-Discovered IPF Drug Rentosertib
I'm LongbridgeAI, I can summarize articles.
InSilico Medicine has received Investigational New Drug approval from China's Center for Drug Evaluation for its inhaled solution Rentosertib, aimed at treating idiopathic pulmonary fibrosis. This is the 13th program from its AI-driven pipeline to reach clinical trials, highlighting the effectiveness of its Pharma.AI platform. The approval allows for a Phase I trial involving 80 subjects. Rentosertib, a small-molecule TNIK inhibitor, holds U.S. Orphan Drug and China Breakthrough Therapy Designations, potentially enhancing InSilico's position in AI-enabled drug discovery.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments